Literature DB >> 28011477

Long Noncoding RNA PANDA Positively Regulates Proliferation of Osteosarcoma Cells.

Yojiro Kotake1,2, Taiki Goto3, Madoka Naemura2, Yasutoshi Inoue2, Haruna Okamoto2, Keiichiro Tahara2.   

Abstract

BACKGROUND: A long noncoding RNA, p21-associated ncRNA DNA damage-activated (PANDA), associates with nuclear transcription factor Y subunit alpha (NF-YA) and inhibits its binding to promoters of apoptosis-related genes, thereby repressing apoptosis in normal human fibroblasts. Here, we show that PANDA is involved in regulating proliferation in the U2OS human osteosarcoma cell line.
MATERIALS AND METHODS: U2OS cells were transfected with siRNAs against PANDA 72 h later and they were subjected to reverse transcription-polymerase chain reaction (RT-PCR), quantitative RT-PCR and cell-cycle analysis.
RESULTS: PANDA was highly expressed in U2OS cells, and its expression was induced by DNA damage. Silencing PANDA caused arrest at the G1 phase of the cell cycle, leading to inhibition of cell proliferation. Quantitative RT-PCR showed that silencing PANDA increased mRNA levels of the cyclin-dependent kinase inhibitor p18, which caused G1 phase arrest.
CONCLUSION: These results suggest that PANDA promotes G1-S transition by repressing p18 transcription, and thus promotes U2OS cell proliferation. Copyright
© 2017 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Long non-coding RNA; PANDA; osteosarcoma; p18; transcription

Mesh:

Substances:

Year:  2017        PMID: 28011477     DOI: 10.21873/anticanres.11292

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

Review 1.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

Review 2.  Long non-coding PANDAR as a novel biomarker in human cancer: A systematic review.

Authors:  Yifan Zou; Yuantang Zhong; Junjie Wu; Huizhong Xiao; Xintao Zhang; Xinhui Liao; Jianfa Li; Xuhua Mao; Yuchen Liu; Fuyou Zhang
Journal:  Cell Prolif       Date:  2017-12-10       Impact factor: 6.831

3.  Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway.

Authors:  Yingjun Wang; Mingzhi Zhang; Huanan Xu; Yifei Wang; Zhaoming Li; Yu Chang; Xinhuan Wang; Xiaorui Fu; Zhiyuan Zhou; Siyuan Yang; Bei Wang; Yufeng Shang
Journal:  Oncotarget       Date:  2017-08-07

Review 4.  Long Noncoding RNAs and RNA-Binding Proteins in Oxidative Stress, Cellular Senescence, and Age-Related Diseases.

Authors:  Chongtae Kim; Donghee Kang; Eun Kyung Lee; Jae-Seon Lee
Journal:  Oxid Med Cell Longev       Date:  2017-07-25       Impact factor: 6.543

Review 5.  The Role of Long Non-Coding RNAs in Osteosarcoma.

Authors:  Maria Anna Smolle; Martin Pichler
Journal:  Noncoding RNA       Date:  2018-03-08

Review 6.  Implications of Long Non-Coding RNAs in Age-Altered Proteostasis.

Authors:  Cristina-Sorina Catana; Catalina-Angela Crișan; Dana Opre; Ioana Berindan-Neagoe
Journal:  Aging Dis       Date:  2020-05-09       Impact factor: 6.745

Review 7.  Long non-coding RNAs in hematological malignancies: translating basic techniques into diagnostic and therapeutic strategies.

Authors:  Nonthaphat Kent Wong; Chien-Ling Huang; Rashidul Islam; Shea Ping Yip
Journal:  J Hematol Oncol       Date:  2018-11-22       Impact factor: 17.388

8.  A novel compound, ferulic acid-bound resveratrol, induces the tumor suppressor gene p15 and inhibits the three-dimensional proliferation of colorectal cancer cells.

Authors:  Yuuga Sawata; Taiji Matsukawa; Satoshi Doi; Toshiyuki Tsunoda; Nagisa Arikawa; Natsumi Matsunaga; Koichiro Ohnuki; Senji Shirasawa; Yojiro Kotake
Journal:  Mol Cell Biochem       Date:  2019-08-22       Impact factor: 3.396

9.  Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer.

Authors:  Jun Liu; Qiwen Ben; Eryi Lu; Xiangyi He; Xiaoqun Yang; Jun Ma; Wen Zhang; Zhiming Wang; Tianshu Liu; Jianjun Zhang; Hongxia Wang
Journal:  Cell Death Dis       Date:  2018-02-07       Impact factor: 8.469

10.  Silencing DSCAM-AS1 suppresses the growth and invasion of ER-positive breast cancer cells by downregulating both DCTPP1 and QPRT.

Authors:  Zhang Yue; Jia Shusheng; Song Hongtao; Zhao Shu; Huang Lan; Zhang Qingyuan; Cheng Shaoqiang; Huang Yuanxi
Journal:  Aging (Albany NY)       Date:  2020-07-27       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.